Xencor Inc (XNCR) stock
XNCRNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 5/30188% above fair value
$33.26−0.75 (-2.21%)
Close on Nov 20, 2026Market cap $2.47BP/E –Yield –
Xencor revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Xencor's revenue for the twelve months ending Jun 30, 2026 was $104.97M, down 28.6% year over year. For fiscal 2025 it was $125.58M, up 13.7% from the year before. The highest annual figure on record is $275.11M in fiscal 2021.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $125.58M | +13.7% |
| FY2024 | Dec 31, 2024 | $110.49M | -36.7% |
| FY2023 | Dec 31, 2023 | $174.62M | +6.1% |
| FY2022 | Dec 31, 2022 | $164.58M | -40.2% |
| FY2021 | Dec 31, 2021 | $275.11M | +124.2% |
| FY2020 | Dec 31, 2020 | $122.69M | -21.7% |
| FY2019 | Dec 31, 2019 | $156.70M | +285.9% |
| FY2018 | Dec 31, 2018 | $40.60M | -12.0% |
| FY2017 | Dec 31, 2017 | $46.15M | -57.7% |
| FY2016 | Dec 31, 2016 | $109.02M | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $51.22M | +17.5% |
| Q1 FY2026 | Mar 31, 2026 | $4.52M | -86.2% |
| Q4 FY2025 | Dec 31, 2025 | $28.24M | -46.5% |
| Q3 FY2025 | Sep 30, 2025 | $21.00M | +18.0% |
| Q2 FY2025 | Jun 30, 2025 | $43.61M | +82.4% |
| Q1 FY2025 | Mar 31, 2025 | $32.73M | +104.6% |
| Q4 FY2024 | Dec 31, 2024 | $52.79M | +3.6% |
| Q3 FY2024 | Sep 30, 2024 | $17.80M | -69.9% |
| Q2 FY2024 | Jun 30, 2024 | $23.91M | -47.5% |
| Q1 FY2024 | Mar 31, 2024 | $16.00M | -15.6% |
| Q4 FY2023 | Dec 31, 2023 | $50.97M | +135.8% |
| Q3 FY2023 | Sep 30, 2023 | $59.16M | +116.7% |
| Q2 FY2023 | Jun 30, 2023 | $45.52M | +50.9% |
| Q1 FY2023 | Mar 31, 2023 | $18.96M | -77.8% |
| Q4 FY2022 | Dec 31, 2022 | $21.61M | -86.0% |
| Q3 FY2022 | Sep 30, 2022 | $27.30M | +38.7% |
| Q2 FY2022 | Jun 30, 2022 | $30.18M | -55.3% |
| Q1 FY2022 | Mar 31, 2022 | $85.50M | +151.7% |
| Q4 FY2021 | Dec 31, 2021 | $154.02M | +268.0% |
| Q3 FY2021 | Sep 30, 2021 | $19.68M | -44.3% |
| Q2 FY2021 | Jun 30, 2021 | $67.45M | +415.3% |
| Q1 FY2021 | Mar 31, 2021 | $33.97M | +4.9% |
| Q4 FY2020 | Dec 31, 2020 | $41.85M | +1090.4% |
| Q3 FY2020 | Sep 30, 2020 | $35.37M | +62.5% |
| Q2 FY2020 | Jun 30, 2020 | $13.09M | -32.8% |
| Q1 FY2020 | Mar 31, 2020 | $32.39M | -71.1% |
| Q4 FY2019 | Dec 31, 2019 | $3.52M | -69.6% |
| Q3 FY2019 | Sep 30, 2019 | $21.76M | -25.1% |
| Q2 FY2019 | Jun 30, 2019 | $19.49M | -35.4% |
| Q1 FY2019 | Mar 31, 2019 | $111.94M | – |
| Q4 FY2018 | Dec 31, 2018 | $11.56M | -7.5% |
| Q3 FY2018 | Sep 30, 2018 | $29.04M | +729.7% |
| Q4 FY2017 | Dec 31, 2017 | $30.15M | – |
| Q3 FY2017 | Sep 30, 2017 | $0 | – |
| Q2 FY2017 | Jun 30, 2017 | $12.50M | – |
| Q1 FY2017 | Mar 31, 2017 | $3.50M | – |
See a number that looks wrong?